The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals.
Second-hand smoke exposure causes approximately 1.2 million deaths globally each year. Exposure to second-hand smoke during pregnancy has negative health effects both for the mother…
Erasmus University Medical Center researchers in Rotterdam have tracked vitamin D supplementation improvements in bone mineral density among patients with erythropoietic protoporphyria.
The U.S. Food and Drug Administration on Tuesday extended the review of Merus NV’s gene-targeting cancer therapy to allow sufficient time to review information submitted…
Opinion: Contraception faces daily attacks on platforms like TikTok and YouTube, where influencers highlight the perceived dangers of hormonal birth control.
Three people were sentenced in relation to drug charges on 25 October after an international police investigation found that the Londoners had conspired to import…
A new study shows that the RSV vaccine reduces the risk of both infection and complications in older adults with inflammatory bowel disease (IBD), but…
CVS Health’s David Joyner is expected to address how he will better manage rising patient costs in the Medicare business than his predecessor when he…
The charity already runs a coffee shop in the town centre, as well as two retail stores.
Join Cell Press and The Lancet for a conversation in which we will hear from Sarah Chellappa and Catherine Crompton about the latest neuroscientific understanding…
bioRxiv – the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution
